ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519901-36-00

Acronym

ETOP 27-23 ARCH

Enrollment

300

Registered

2025-10-08

Start date

2025-12-17

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

Brief summary

Disease free survival (in patients with tumours with centrally confirmed PD-L1 expression of ≥1%)

Detailed description

Overall survival, Incidence, nature and severity of adverse events according to CTCAE v5

Interventions

DRUGLIBTAYO 350 mg concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease free survival (in patients with tumours with centrally confirmed PD-L1 expression of ≥1%)	—

Secondary

Measure	Time frame
Overall survival, Incidence, nature and severity of adverse events according to CTCAE v5	—

Countries

Austria, Estonia, France, Germany, Ireland, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026